§ 13F · FUND PROFILE
SR One Capital Management, LP.
Institutional filer · behavioral pattern: Other. Summary pending.
AUM · $691M (13F)Positions · 12Turnover · — · Q1Filed · May 14, 2026
CONCENTRATION
—
Top 10 holdings
NEW BUYS
0
+$152M deployed
EXITS
0
No exits
SECTOR SHIFT
—
No prior quarter data
3YR HIT RATE
—
Top-5 overlap
§ 01 · TOP HOLDINGS
The book · Q1 2026
FILED MAY 14, 2026
| # | Ticker | Name | Shares | $ value | % port | Δ Q1 |
|---|---|---|---|---|---|---|
| 1 | ACLX | Arcellx, Inc. | 2.35M | $269M | 29.4% | ±0% |
| 2 | MANE | Veradermics, Inc. | 2.40M | $152M | 16.6% | NEW |
| 3 | ZBIO | Zenas BioPharma, Inc | 5.04M | $98M | 10.8% | ±0% |
| 4 | CRSP | CRISPR Therapeutics AG | 2.04M | $97M | 10.6% | ±0% |
| 5 | DSGN | Design Therapeutics, Inc. | 6.53M | $69M | 7.6% | ±0% |
| 6 | ORIC | ORIC Pharmaceuticals, Inc. | 4.51M | $58M | 6.4% | ±0% |
| 7 | ALMS | Alumis Inc. | 1.96M | $43M | 4.7% | ±0% |
| 8 | MLYS | Mineralys Therapeutics Inc. | 1.56M | $42M | 4.6% | ±0% |
| 9 | SPRY | ARS Pharmaceuticals, Inc. | 4.01M | $32M | 3.5% | ±0% |
| 10 | ORKA | Oruka Therapeutics, Inc | 430K | $21M | 2.3% | ±0% |
§ 02 · SECTOR ALLOCATION
Where the money is
Sector data pending
§ 03 · THE SR SIGNAL
AC read
SR One Capital Management, LP is a Other fund managing $691 million in assets. The fund runs a focused portfolio of just 12 positions.
Read the full dossier →§ 04 · FILING HISTORY
Q-by-Q deltas
2 FILINGS
Q1 2026
Steady book
+0 buys · −0 exits · 0 changed
Q4 2025
Steady book
+0 buys · −0 exits · 0 changed
Q3 2025
Steady book
+0 buys · −0 exits · 0 changed
Q1 2025
Steady book
+0 buys · −0 exits · 0 changed